Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Woyach on a Study Combining MOR208 With Lenalidomide for the Treatment of CLL
December 7th 2016Jennifer Woyach, MD, associate professor, Ohio State University, discusses a study examining the use of MOR208 combined with lenalidomide (Revlimid) for the treatment of chronic lymphotic leukemia (CLL) during the American Society of Hematology (ASH) Annual Meeting.
Osimertinib Beats Chemo in Second-Line T790M-Mutant NSCLC
December 7th 2016Osimertinib (Tagrisso) reduced the risk of disease progression by 70% compared with a chemotherapy doublet in patients with EGFR T790M-mutant non–small cell lung cancer (NSCLC) who progressed after first-line targeted therapy.
Dr. Juergens on the IND.226 Trial in Advanced Non-Squamous NSCLC
December 6th 2016Rosalyn Juergens, MD, PhD, assistant professor, Department of Oncology, Division of Medical Oncology, McMaster University, discusses the results of the IND.226 trial, in an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.
Dr. Verschraegen on the JAVELIN Solid Tumor Trial in Advanced NSCLC
December 6th 2016Claire Verschraegen, MD, professor of Medical Oncology, University of Vermont Cancer Center, discusses the results of the JAVELIN Solid Tumor trial during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.
Selinexor Active in Heavily Pretreated Myeloma
December 6th 2016Selinexor, in combination with dexamethasone, induced a response rate of 20.5% (n = 16) among 78 heavily pretreated patients with relapsed/refractory multiple myeloma, according to results from the phase IIb STORM trial presented at the 2016 ASH Annual Meeting.
Dr. Gisslinger on a Study Comparing Ropeginterferon Alfa-2b to Hydroxyurea in PV
December 6th 2016Heinz Gisslinger, MD, Medical University of Vienna, discusses the phase III PROUD-PV study, which evaluated ropeginterferon alfa-2b (P1101) for the treatment of polycythemia vera (PV) during the American Society of Hematology (ASH) Annual Meeting.
KTE-C19 Response Rates Spark FDA Submission for Aggressive Lymphomas
Treatment with the CD19-directed CAR T-cell therapy KTE-C19 showed a complete remission rate of 73% for patients with aggressive, chemorefractory primary mediastinal B-cell lymphoma and transformed follicular lymphoma.
Improved PFS, ORR With Frontline Nivolumab and Nivolumab/Ipilimumab Combo in NSCLC
December 6th 2016Findings from an efficacy update of patients participating in a study in the CheckMate series revealed that first-line nivolumab (Opdivo) demonstrated activity in advanced non–small cell lung cancer, and the addition of ipilimumab (Yervoy) resulted in enhanced activity, specifically in prolonged progression-free survival and higher objective response rates.
Early Study Signals Promising Role for Venetoclax in Treatment of Relapsed CLL
December 6th 2016Adding the oral BCL-2 inhibitor venetoclax (Venclexta) to obinutuzumab (Gazyva) and ibrutinib (Imbruvica) in patients with relapsed/refractory chronic lymphocytic leukemia is safe and is demonstrating encouraging signs of efficacy.
Acalabrutinib Safe, Effective in Ibrutinib-Intolerant CLL/SLL
The investigational Bruton tyrosine kinase inhibitor acalabrutinib was shown to be well-tolerated in patients with chronic lymphocytic leukemia and small lymphocytic leukemia who display intolerance to ibrutinib (Imbruvica).
TGR-1202/Ibrutinib Combo Feasible, Highly Active for CLL/MCL
The combination of the PI3 kinase inhibitor TGR-1202 and ibrutinib demonstrated a high response rate without dose-limiting toxicities for patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.
Dr. Roth on the Rationale Behind a Novel Risk-Prediction Model in Lung Cancer Screening
December 5th 2016Joshua Roth, PhD, assistant member, Fred Hutchinson Cancer Research Center, discusses the rationale behind the development of a novel risk-prediction algorithm in the context of screening patients for lung cancer. He discussed this during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.
Dr. Zulueta on the Non-Invasive LuCED Test for Detection of Early Stage Lung Cancer
December 5th 2016Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses the LuCED test, a non-invasive tool used to detect early stage lung cancer, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.
Dr. Burke on a Study Investigating Obinutuzumab in Large B-Cell Lymphoma
December 5th 2016John M. Burke, MD, discusses the GOYA study, a phase III study investigating obinutuzumab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma. Burke discussed the study during the American Society of Hematology (ASH) Annual Meeting.
Frontline Obinutuzumab Significantly Improves PFS in Follicular Lymphoma
December 5th 2016Combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 34% versus rituximab plus chemotherapy in patients with follicular lymphoma, according to findings from the phase III GALLIUM study.
Pembrolizumab Combo Highly Effective for Heavily Pretreated Myeloma
Treatment with the combination of pembrolizumab, pomalidomide, and dexamethasone demonstrated promising durable efficacy and a tolerable safety profile for patients with relapsed/refractory multiple myeloma.
Dr. Thompson on Exciting Advancements in the Field of Multiple Myeloma
December 5th 2016Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses some of the recent exciting advancements in the field of multiple myeloma during the American Society of Hematology (ASH) Annual Meeting.
After 5 Years of Follow-Up, Ibrutinib Continues to Impress in CLL/SLL
December 5th 2016Ibrutinib showed an 89% response rate in both treatment-naïve and relapsed patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in findings from the longest follow-up to date for the BTK inhibitor.
Lirilumab/Azacytidine Combo Safe, Active in AML
December 5th 2016The combination of the killer-cell immunoglobulin-like receptors inhibitor lirilumab with the hypomethylating agent azacytidine was well tolerated and showed early signals of activity in heavily pretreated patients with acute myeloid leukemia.
